Other languages UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Real-time Estimate Cboe BZX Other stock markets 10:04:09 2024-06-10 am EDT			5-day change	1st Jan Change
13.2 ^USD	-0.11%		+0.23%	-12.27%

Jun. 03	UroGen Pharma Appoints David Lin as New Chief Commercial Officer	CI
May. 14	Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UroGen Pharma Appoints David Lin as New Chief Commercial Officer	Jun. 03
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07
UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	May. 05
UroGen Pharma Ltd. Reports New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer	May. 04
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	Apr. 15
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14
UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug	Jan. 24
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102	Jan. 24
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H	Jan. 17
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024	Jan. 17
UroGen Signs Licensing Deal With Medac to Develop New Formulation for Urothelial Cancer; Shares Rise	Jan. 17
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023	Nov. 14
UroGen Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023	23-08-10
UroGen Pharma Shares Surge Amid Data From Bladder Cancer Drug Trials, $120 Million Private Stock Sale	23-07-27
UroGen Pharma Ltd. Announces Positive Topline Data From its Phase 3 Trials ATLAS and ENVISION studying UGN-102	23-07-27
UroGen Pharma Ltd. Announces the Appointment of James Robinson to Its Board of Directors	23-07-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Other languages

Filters